Evolus (EOLS) and American Bio Medica (ABMC) Critical Contrast

Evolus (NASDAQ:EOLS) and American Bio Medica (OTCMKTS:ABMC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation.


This table compares Evolus and American Bio Medica’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Evolus N/A -79.85% -14.93%
American Bio Medica -23.15% -281.86% -32.09%

Insider and Institutional Ownership

24.9% of Evolus shares are held by institutional investors. 10.8% of American Bio Medica shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Evolus and American Bio Medica’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Evolus N/A N/A -$4.48 million ($0.27) -98.37
American Bio Medica $4.91 million 0.58 -$540,000.00 N/A N/A

American Bio Medica has higher revenue and earnings than Evolus.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Evolus and American Bio Medica, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evolus 0 0 5 0 3.00
American Bio Medica 0 0 0 0 N/A

Evolus presently has a consensus price target of $31.40, suggesting a potential upside of 18.22%. Given Evolus’ higher possible upside, analysts clearly believe Evolus is more favorable than American Bio Medica.


Evolus beats American Bio Medica on 6 of the 9 factors compared between the two stocks.

Evolus Company Profile

Evolus, Inc. provides medical aesthetic products for physicians and their patients in the United States. It offers DWP-450, an injectable 900 kilodalton botulinum toxin type A complex designed to address the needs of the facial aesthetics market. The company was founded in 2012 and is headquartered in Irvine, California.

American Bio Medica Company Profile

American Bio Medica Corporation develops, manufactures, and sells lateral flow immunoassay tests primarily for the immediate detection of drugs in urine and oral fluids at the point of collection. Its drugs detection products in urine include Rapid Drug Screen, a rapid drug test, which detects the presence or absence of 2 to 10 drugs; Rapid ONE product line that consists of single drug tests, each of which tests for the presence or absence of a single drug; RDS InCup, a drug-testing cup that detects the presence or absence of 1 to 12 drugs; Rapid TOX, a drug test in a cassette platform, which detects the presence or absence of 2 to 10 drugs; Rapid TOX Cup II, a drug testing cup that detects the presence or absence of 1 to 14 drugs; and Rapid TOX Cup II (2G), a second generation of the original Rapid TOX Cup II, which consists of a smaller cup with smaller test strip, as well as private labeled versions of Rapid TOX. The company also offers OralStat, a drug test for the detection of drugs in oral fluids, as well as private labeled versions of OralStat. In addition, the company distributes other products for the detection of substances of abuse; and products that detect the presence or absence of alcohol, and alternative sample options for drug testing, as well as toxicology management services. Further, it provides bulk test strip contract manufacturing services to non-affiliated diagnostic companies. American Bio Medica Corporation serves rehabilitation/drug treatment, pain management, other clinical, government, and employment/workplace markets in the United States and internationally. The company was formerly known as American Micro Media, Inc. and changed its name to American Bio Medica Corporation in September 1992. American Bio Medica Corporation was founded in 1986 and is based in Kinderhook, New York.

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit